Targeting the RUNX2–TGF-β regulatory circuit to overcome cancer stem cell-mediated chemoresistance in triple-negative breast cancer: mechanisms, therapeutic opportunities, and translational challenges

Abstract Background. Chemoresistance in triple-negative breast cancer (TNBC) remains a critical driver of relapse and metastasis. Current explanatory models—EMT reversibility, the absence of upstream CSC drivers, TGF-β pleiotropy, and fragmented RUNX2 functions—exist in isolation, lacking a unified framework. Main body This review proposes the RUNX2-TGF-β positive feedback loop as a working hypothesis for a regulatory node that integrates these mechanisms. In this proposed circuit, TGF-β is postulated to activate RUNX2, which in turn amplifies TGF-β signaling, forming a self-reinforcing loop that is proposed to sustain CSC stemness, plasticity, metabolic adaptation, and drug tolerance. We synthesize the molecular evidence for this circuit, propose a candidate causal chain in chemoresistance, and critically evaluate cross-cancer evidence while distinguishing it from TNBC-specific findings. We then critically analyze why most targeted strategies succeed preclinically yet fail clinically, covering TGF-β inhibitor toxicity, RUNX2 “undruggability,” weak natural compound evidence, and the model-to-clinic gap. Conclusion Given the limited direct causal evidence in TNBC, the RUNX2-TGF-β circuit is presented here as a working hypothesis rather than an established resistance mechanism. We propose a translational validation roadmap and highlight key unresolved questions. Unlike previous reviews, this work explicitly grades the evidence for each link in the circuit and designs a falsifiable experiment to test whether circuit disruption reverses established chemoresistance.

Authors

Institutions

Publication Details

Journal
Journal of Translational Medicine
Published
2026-11-12
DOI
https://doi.org/10.1186/s12967-026-09203-w
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting the RUNX2–TGF-β regulatory circuit to overcome cancer stem cell-mediated chemoresistance in triple-negative breast cancer: mechanisms, therapeutic opportunities, and translational challenges

JiaRui Zhang, Rilei Jiang, Yiting Cao, Ying Xu et al.
Journal of Translational Medicine
Cancer Cells and Metastasis
article

Targeting the RUNX2–TGF-β regulatory circuit to overcome cancer stem cell-mediated chemoresistance in triple-negative breast cancer: mechanisms, therapeutic opportunities, and translational challenges

JiaRui Zhang, Rilei Jiang, Yiting Cao, Ying Xu, Qian Li, Jun Hu, Danni Cen
article en

Abstract

Abstract Background. Chemoresistance in triple-negative breast cancer (TNBC) remains a critical driver of relapse and metastasis. Current explanatory models—EMT reversibility, the absence of upstream CSC drivers, TGF-β pleiotropy, and fragmented RUNX2 functions—exist in isolation, lacking a unified framework. Main body This review proposes the RUNX2-TGF-β positive feedback loop as a working hypothesis for a regulatory node that integrates these mechanisms. In this proposed circuit, TGF-β is postulated to activate RUNX2, which in turn amplifies TGF-β signaling, forming a self-reinforcing loop that is proposed to sustain CSC stemness, plasticity, metabolic adaptation, and drug tolerance. We synthesize the molecular evidence for this circuit, propose a candidate causal chain in chemoresistance, and critically evaluate cross-cancer evidence while distinguishing it from TNBC-specific findings. We then critically analyze why most targeted strategies succeed preclinically yet fail clinically, covering TGF-β inhibitor toxicity, RUNX2 “undruggability,” weak natural compound evidence, and the model-to-clinic gap. Conclusion Given the limited direct causal evidence in TNBC, the RUNX2-TGF-β circuit is presented here as a working hypothesis rather than an established resistance mechanism. We propose a translational validation roadmap and highlight key unresolved questions. Unlike previous reviews, this work explicitly grades the evidence for each link in the circuit and designs a falsifiable experiment to test whether circuit disruption reverses established chemoresistance.

Journal of Translational Medicine
Tongji University (CN), Nanjing University of Chinese Medicine (CN), Cornell University (US), Shanghai University of Traditional Chinese Medicine (CN), Shuguang Hospital (CN), Shanghai First Maternity and Infant Hospital (CN)
Good health and well-being
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon